Trials / Completed
CompletedNCT00478725
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects With Solid Tumor Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW786034, oral | oral, 800 mg |
| DRUG | GW786034, IV | IV, 5 mg |
| DRUG | GW786034, radiolabeled oral | oral, 400 mg radiolabeled |
Timeline
- Start date
- 2007-07-18
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-05-25
- Last updated
- 2017-11-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00478725. Inclusion in this directory is not an endorsement.